Effect of Human Bone Morphogenetic Protein 2 Implant on Tooth Eruption in an Experimental Design

rhBMP‐2 significantly enhances guided bone regeneration

“…Following purification and subsequent molecular cloning (Wozney et al 1988;Celeste et al 1990;Ö zkaynak et al 1990), the proteins representing this activity were identified ) and made available for preclinical evaluation. One of these proteins, recombinant human BMP-2 (rhBMP-2), has been shown to induce clinically relevant bone formation in a multitude of craniofacial and periodontal settings in large animal models (Toriumi et al 1991(Toriumi et al , 1999Ishikawa et al 1994;Sigurdsson et al 1995Sigurdsson et al , 1996Sigurdsson et al , 1997Sigurdsson et al , 2001Mayer et al 1996;Boyne 1996;Boyne et al 1998Boyne et al , 1999Boyne & Shabahang 2001;Nevins et al 1996;Cochran et al 1997Cochran et al , 1999Hanisch et al 1997aHanisch et al , 1997bHanisch et al , 2002Kinoshita et al 1997;Kirker-Head et al 1997;Steinberg et al 1999;Wikesjö et al 1999Wikesjö et al , 2002Wikesjö et al , 2003aWikesjö et al , 2003bWikesjö et al , 2003cWikesjö et al , 2003dYudell & Block 2000;Barboza et al 2000;Hunt et al 2001;Sykaras et al 2001;Choi et al 2002;Jovanovic et al 2003;Selvig et al 2002;Tatakis et al 2002). Sigurdsso...…”

Periodontal repair in dogs: space‐providing ePTFE devices increase rhBMP‐2/ACS‐induced bone formation

“…Following purification and molecular cloning (Wozney et al 1988; Celeste et al 1990, Özkaynak et al 1990), the proteins representing this bone‐inductive activity have been identified (Wang et al 1990), and produced for preclinical and clinical evaluation. One of these proteins, recombinant human BMP‐2 (rhBMP‐2), has been shown to induce clinically relevant bone formation in a variety of craniofacial and periodontal indications in large animal models including mandibular resection defects (Toriumi et al 1991, 1999, Boyne 1996, Boyne et al 1999), cleft palate defects (Mayer et al 1996, Boyne et al 1998), orthognatic defects (Yudell & Block 2000), alveolar ridge (Cochran et al 1997, 1999, Hanisch et al 1997a, 2003, Sigurdsson et al 1997, 2001, Steinberg et al 1999, Barboza et al 2000, Boyne & Shabahang 2001, Hunt et al 2001, Tatakis et al 2002, Jovanovic et al 2003, Wikesjö et al 2003a, b) and subantral augmentation (Nevins et al 1996, Kirker‐Head et al 1997, Hanisch et al 1997b), and application to periodontal defects (Ishikawa et al 1994, Sigurdsson et al 1995a, b, 1996, Kinoshita et al 1997, Wikesjö et al 1999, 2003c, d, Choi et al 2002, Selvig et al 2002). Induced bone integrates with the resident bone.…”

“…, orthognatic defects (Yudell & Block 2000), alveolar ridge , Hanisch et al 1997a, Sigurdsson et al 1997, Steinberg et al 1999, Barboza et al 2000, Boyne & Shabahang 2001, Hunt et al 2001, Tatakis et al 2002, Jovanovic et al 2003, Wikesjö et al 2003a and subantral augmentation (Nevins et al 1996, Kirker-Head et al 1997, Hanisch et al 1997b, and application to periodontal defects (Ishikawa et al 1994, Sigurdsson et al 1995a, b, 1996, Kinoshita et al 1997, 2003c, d, Choi et al 2002, Selvig et al 2002. Induced bone integrates with the resident bone.…”

“…Various biomaterials have been tested as carriers for rhBMP-2 in craniofacial preclinical models. These include an absorbable collagen sponge (ACS) (Boyne 1996, Sigurdsson et al 1996, Nevins et al 1996, Hanisch et al 1997a, b, 2003, Kirker-Head et al 1997, Boyne et al 1998, Steinberg et al 1999, 2003a, b, d, Barboza et al 2000, Yudell & Block 2000, Hunt et al 2001, Sykaras et al 2001, Choi et al 2002, Jovanovic et al 2003, Selvig et al 2002, Tatakis et al 2002, decalcified bone matrix (Toriumi et al 1991, Sigurdsson et al 1996, bone mineral matrix (Sigurdsson et al 1996, Barboza et al 2000, Boyne & Shabahang 2001, hyaluronan (Hunt et al 2001, Wikesjö et al 2003c), hydroxyapatite (Koempel et al 1998), calcium phosphates , calcium carbonates (Boyne & Shabahang 2001), poly(a-hydroxy acids) (Ishikawa et al 1994, Sigurdsson et al 1995a, b, 1996, Mayer et al 1996, Kinoshita et al 1997, Toriumi et al 1999, methylethylmethacrylate (Boyne & Shabahang 2001), and titanium (Wikesjö, personal communication). Successful candidate carrier systems must enable vascular and cellular invasion to facilitate rhBMP-2 bone induction.…”

Tissue Engineering with Recombinant Human Bone Morphogenetic Protein‐2 for Alveolar Augmentation and Oral Implant Osseointegration: Experimental Observations and Clinical Perspectives*

“…Clinical-type defects that may not necessarily be discriminating criticalsize defects but are recognized as difficult to manage successfully are produced in large animals to evaluate the efficacy and application of a candidate therapy. Examples of clinical modeling used to evaluate rhBMP-2 in the craniofacial skeleton include mandibular segmental defect reconstruction, [6][7][8][9] cleft palate reconstruction, [10][11][12] zygoma bone gap reconstruction, 13 subantral augmentation, 14,15 alveolar ridge augmentation, [16][17][18][19][20][21][22][23] periimplantitis defect reconstruction, 18 and oral implant functional loading. 19 In the following we present studies evaluating the effect of rhBMP-2 in discriminating critical-size defect models and using clinical modeling.…”